Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590702 | 0.90 | GABRA1 (0.48) | GAAPTPN7DUSP3GABRA1GABRB2 | |
| SCHEMBL627496 | 0.90 | GAA (0.56) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL12128276 | 0.81 | CTSL (0.47) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL22861023 | 0.78 | GABRB2 (0.52) | GAACES2GABRA1GABRB2ALDH1A1 | |
| SCHEMBL1104677 | 0.78 | GABRB2 (0.52) | GAACES2GABRA1GABRB2ALDH1A1 | |
| SCHEMBL12128243 | 0.78 | GAA (0.46) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL16952205 | 0.78 | CES2 (0.50) | GAACES2PTPN7DUSP3GABRA1 | |
| SCHEMBL3589490 | 0.78 | EPHX2 (0.42) | GAAPTPN7DUSP3GABRA1GABRB2 | |
| SCHEMBL11298235 | 0.77 | GAA (0.53) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL1198001 | 0.77 | NOTUM (0.53) | GAACES2CTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | GAA 4433/4885CES2 3076/4885PTPN7 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.